特应性皮炎共病的研究进展

doi:10.35541/cjd.20230099

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (11): 1058-1063.doi: 10.35541/cjd.20230099

• 综述 • 上一篇

特应性皮炎共病的研究进展

谢欣然张璐杜丹李晓雪李焰梅蒋献

四川大学华西医院皮肤性病科四川大学疾病分子网络前沿科学中心免疫炎症研究院皮肤病学研究室，成都 610041

收稿日期:2023-02-23 修回日期:2024-04-20 发布日期:2024-10-31
通讯作者: 蒋献 E-mail:jiangxian@scu.edu.cn
基金资助:
国家自然科学基金（82073473）；四川大学自贡市校地科技合作专项资金（2021CDZG-21）

Comorbidities in atopic dermatitis

Xie Xinran, Zhang Lu, Du Dan, Li Xiaoxue, Li Yanmei, Jiang Xian

Department of Dermatology and Venereology, West China Hospital, Sichuan University, Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China

Received:2023-02-23 Revised:2024-04-20 Published:2024-10-31
Contact: Jiang Xian E-mail:jiangxian@scu.edu.cn
Supported by:
National Natural Science Foundation of China （82073473）; Sichuan University-Zigong Special Fund for University-local Science and Technology Cooperation （2021CDZG-21）

摘要/Abstract

摘要： 【摘要】特应性皮炎（AD）是一种常见的慢性炎症性皮肤病，常与哮喘、变应性鼻炎、食物过敏等特应性疾病共存。近年来，越来越多研究显示AD与心血管疾病、自身免疫疾病、精神心理疾病等多种疾病存在关联，加重AD患者疾病负担并严重影响其生活质量。本文总结既往文献报道的AD相关共病，分析其可能的共同发病机制和潜在治疗方法。

关键词: 皮炎, 特应性, 共病现象, 特应性疾病, 心血管疾病, 自身免疫疾病, 精神心理疾病

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic inflammatory disease that often coexists with atopic diseases such as asthma, allergic rhinitis, and food allergies. In recent years, more and more studies have shown that AD is associated with various diseases such as cardiovascular diseases, autoimmune diseases, and mental disorders, which exacerbate the disease burden on patients with AD and severely affect their quality of life. This review summarizes AD-associated comorbidities reported in previous literature, analyzes their possible common pathogenesis, and explores potential treatments.

Key words: Dermatitis, atopic, Comorbidity, Atopic diseases, Cardiovascular diseases, Autoimmune diseases, Mental illness

谢欣然张璐杜丹李晓雪李焰梅蒋献. 特应性皮炎共病的研究进展[J]. 中华皮肤科杂志, 2024,57(11):1058-1063. doi:10.35541/cjd.20230099

Xie Xinran, Zhang Lu, Du Dan, Li Xiaoxue, Li Yanmei, Jiang Xian. Comorbidities in atopic dermatitis[J]. Chinese Journal of Dermatology, 2024, 57(11): 1058-1063.doi:10.35541/cjd.20230099

参考文献 92

［1］	Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease［J］. Nat Rev Drug Discov, 2022,21（1）:21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6.
［2］	Milder E. Atopic dermatitis （generalized neurodermatitis）: the atopic dermatitis⁃asthma⁃hay fever syndrome［J］. Med J Aust, 1958,45（3）:72⁃76.
［3］	Thyssen JP, Halling AS, Schmid⁃Grendelmeier P, et al. Comorbidities of atopic dermatitis⁃what does the evidence say?［J］. J Allergy Clin Immunol, 2023,151（5）:1155⁃1162. doi: 10. 1016/j.jaci.2022.12.002.
［4］	Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis［J］. Nat Rev Dis Primers, 2018,4（1）:1. doi: 10.1038/s41572⁃018⁃0001⁃z.
［5］	Davis D, Drucker AM, Alikhan A, et al. American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults［J］. J Am Acad Dermatol, 2022,86（6）:1335⁃1336.e18. doi: 10.1016/j.jaad.2022.01.009.
［6］	Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults［J］. Ann Allergy Asthma Immunol, 2018,121（5）:604⁃612.e3. doi: 10.1016/j.anai.2018.07.042.
［7］	Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Allergy Asthma Immunol, 2021,127（1）:49⁃56.e1. doi: 10.1016/j.anai.2021.02.026.
［8］	Wu KK, Borba AJ, Deng PH, et al. Association between atopic dermatitis and conjunctivitis in adults: a population⁃based study in the United States［J］. J Dermatolog Treat, 2021,32（4）:455⁃459. doi: 10.1080/09546634.2019.1659480.
［9］	Spergel JM, Blaiss MS, Lio P, et al. Efficacy and safety of crisaborole in patients with mild⁃to⁃moderate atopic dermatitis and other atopic comorbidities［J］. Allergy Asthma Proc, 2021,42（5）:425⁃431. doi: 10.2500/aap.2021.42.210064.
［10］	Narla S, Silverberg JI. Association between atopic dermatitis and autoimmune disorders in US adults and children: a cross⁃sectional study［J］. J Am Acad Dermatol, 2019,80（2）:382⁃389. doi: 10.1016/j.jaad.2018.09.025.
［11］	Roh YS, Huang AH, Sutaria N, et al. Real⁃world comorbidities of atopic dermatitis in the US adult ambulatory population［J］. J Am Acad Dermatol, 2022,86（4）:835⁃845. doi: 10.1016/j.jaad. 2021.11.014.
［12］	Cheng BT, Silverberg NB, Silverberg JI. Association of childhood atopic dermatitis with atopic and nonatopic multimorbidity［J］. Dermatitis, 2021,32（4）:214⁃219. doi: 10.1097/DER.0000000 000000644.
［13］	Wang LC, Chiang BL. Early⁃onset⁃early⁃resolving atopic dermatitis does not increase the risk of development of allergic diseases at 3 years old［J］. J Formos Med Assoc, 2020,119（12）:1854⁃1861. doi: 10.1016/j.jfma.2020.02.014.
［14］	Kok WL, Yew YW, Thng TG. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study［J］. Acta Derm Venereol, 2019,99（7）:652⁃656. doi: 10.2340/00015555⁃3175.
［15］	Bulger DA, Minhas S, Asbeutah AA, et al. Chronic systemic inflammatory skin disease as a risk factor for cardiovascular disease［J］. Curr Probl Cardiol, 2021,46（5）:100799. doi: 10. 1016/j.cpcardiol.2021.100799.
［16］	Jung HJ, Lee DH, Park MY, et al. Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea［J］. Allergy Asthma Clin Immunol, 2021,17（1）:94. doi: 10.1186/s13223⁃021⁃00590⁃x.
［17］	Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta⁃analysis of population⁃based studies［J］. J Allergy Clin Immunol, 2019,143（5）:1821⁃1829. doi: 10.1016/j.jaci.2018.11.030.
［18］	Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study［J］. BMJ, 2018,361:k1786. doi: 10.1136/bmj.k1786.
［19］	He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2020,124（1）:70⁃78. doi: 10.1016/j.anai.2019.10.013.
［20］	Hedderson MM, Asgari MM, Xu F, et al. Rates of cardiovascular events among patients with moderate⁃to⁃severe atopic dermatitis in an integrated health care system: a retrospective cohort study［J］. PLoS One, 2022,17（11）:e0277469. doi: 10.1371/journal.pone.0277469.
［21］	Pandher K, Ghamrawi RI, Heron CE, et al. Controversial cardiovascular and hematologic comorbidities in atopic dermatitis［J］. Arch Dermatol Res, 2022,314（4）:317⁃324. doi: 10.1007/s00403⁃021⁃02240⁃z.
［22］	Appiah MM, Haft MA, Kleinman E, et al. Atopic dermatitis: review of comorbidities and therapeutics［J］. Ann Allergy Asthma Immunol, 2022,129（2）:142⁃149. doi: 10.1016/j.anai.2022.05.015.
［23］	Rhee TM, Choi EK, Han KD, et al. Impact of the combinations of allergic diseases on myocardial infarction and mortality［J］. J Allergy Clin Immunol Pract, 2021,9（2）:872⁃880.e4. doi: 10. 1016/j.jaip.2020.09.008.
［24］	Villani AP, Pavel AB, Wu J, et al. Vascular inflammation in moderate⁃to⁃severe atopic dermatitis is associated with enhanced Th2 response［J］. Allergy, 2021,76（10）:3107⁃3121. doi: 10. 1111/all.14859.
［25］	He H, Del Duca E, Diaz A, et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities［J］. J Allergy Clin Immunol, 2021,147（4）:1369⁃1380. doi: 10.1016/j.jaci.2020.08.041.
［26］	Qi H, Wang L, Li L. Association between atopic dermatitis and major cardiovascular outcomes: a two⁃sample Mendelian randomization study［J］. Dermatol Pract Concept, 2022,12（4）:e2022165. doi: 10.5826/dpc.1204a165.
［27］	De Bruyn Carlier T, Badloe F, Ring J, et al. Autoreactive T cells and their role in atopic dermatitis［J］. J Autoimmun, 2021,120:102634. doi: 10.1016/j.jaut.2021.102634.
［28］	Holmes J, Fairclough LC, Todd I. Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity［J］. Arch Dermatol Res, 2019,311（3）:141⁃162. doi: 10.1007/s00403⁃019⁃01890⁃4.
［29］	Wu PC, Wu CY, Lyu YS, et al. Association between bullous pemphigoid and atopic dermatitis: a population⁃based case⁃control study in Taiwan［J］. Arch Dermatol Res, 2023,315（3）:419⁃427. doi: 10.1007/s00403⁃022⁃02372⁃w.
［30］	de Lusignan S, Alexander H, Broderick C, et al. Atopic dermatitis and risk of autoimmune conditions: population⁃based cohort study［J］. J Allergy Clin Immunol, 2022,150（3）:709⁃713. doi: 10.1016/j.jaci.2022.03.030.
［31］	Ivert LU, Wahlgren CF, Lindelöf B, et al. Association between atopic dermatitis and autoimmune diseases: a population⁃based case⁃control study［J］. Br J Dermatol, 2021,185（2）:335⁃342. doi: 10.1111/bjd.19624.
［32］	Attah Johnson FY, Mostaghimi H. Co⁃morbidity between dermatologic diseases and psychiatric disorders in Papua New Guinea［J］. Int J Dermatol, 1995,34（4）:244⁃248. doi: 10.1111/j.1365⁃4362.1995.tb01589.x.
［33］	Holmes A, Marella P, Rodriguez C, et al. Alexithymia and cutaneous disease morbidity: a systematic review［J］. Dermatology, 2022,238（6）:1120⁃1129. doi: 10.1159/000524736.
［34］	Ramirez FD, Chen S, Langan SM, et al. Association of atopic dermatitis with sleep quality in children［J］. JAMA Pediatr, 2019,173（5）:e190025. doi: 10.1001/jamapediatrics.2019.0025.
［35］	Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a 2⁃way street?［J］. J Allergy Clin Immunol, 2018,142（4）:1033⁃1040. doi: 10.1016/j.jaci.2018.08.005.
［36］	Sandhu JK, Wu KK, Bui TL, et al. Association between atopic dermatitis and suicidality: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（2）:178⁃187. doi: 10.1001/jamadermatol.2018.4566.
［37］	Pan TL, Bai YM, Cheng CM, et al. Atopic dermatitis and dementia risk: a nationwide longitudinal study［J］. Ann Allergy Asthma Immunol, 2021,127（2）:200⁃205. doi: 10.1016/j.anai. 2021.03.001.
［38］	Pandher K, Patel K, Wang JV, et al. The other side of atopic dermatitis: an evaluation of psychosocial comorbidities［J］. Clin Dermatol, 2021,39（2）:296⁃298. doi: 10.1016/j.clindermatol. 2020.07.002.
［39］	Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2019,80（2）:402⁃410. doi: 10.1016/j.jaad.2018.08.063.
［40］	Qi HJ, Li LF. Association of atopic dermatitis with depression and suicide: a two⁃sample Mendelian randomization study［J］. Biomed Res Int, 2022,2022:4084121. doi: 10.1155/2022/4084121.
［41］	Ascott A, Mansfield KE, Schonmann Y, et al. Atopic eczema and obesity: a population⁃based study［J］. Br J Dermatol, 2021,184（5）:871⁃879. doi: 10.1111/bjd.19597.
［42］	Huang AH, Roh YS, Sutaria N, et al. Real⁃world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States［J］. J Am Acad Dermatol, 2021,85（4）:893⁃900. doi: 10.1016/j.jaad.2021.03.016.
［43］	Shalom G, Dreiher J, Kridin K, et al. Atopic dermatitis and the metabolic syndrome: a cross⁃sectional study of 116 816 patients［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1762⁃1767. doi: 10.1111/jdv.15642.
［44］	Ali Z, Ulrik CS, Agner T, et al. Association between atopic dermatitis and the metabolic syndrome: a systematic review［J］. Dermatology, 2018,234（3⁃4）:79⁃85. doi: 10.1159/000491593.
［45］	Iturriaga C, Bustos MF, Le Roy C, et al. Association between obesity and atopic dermatitis in children: a case⁃control study in a high obesity prevalence population［J］. Pediatr Dermatol, 2023,40（1）:64⁃68. doi: 10.1111/pde.15110.
［46］	Matthewman J, Mansfield KE, Prieto⁃Alhambra D, et al. Atopic eczema⁃associated fracture risk and oral corticosteroids: a population⁃based cohort study［J］. J Allergy Clin Immunol Pract, 2022,10（1）:257⁃266.e8. doi: 10.1016/j.jaip.2021.09.026.
［47］	Mukovozov IM, Morra DE, Giustini D, et al. Atopic dermatitis and bone health: a systematic review［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:615⁃628. doi: 10.1111/jdv.16895.
［48］	Lin TL, Wu CY, Yen JJ, et al. Fracture risks in patients with atopic dermatitis: a nationwide matched cohort study［J］. Ann Allergy Asthma Immunol, 2021,127（6）:667⁃673.e2. doi: 10. 1016/j.anai.2021.09.004.
［49］	Wu D, Wu XD, Zhou X, et al. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Transl Med, 2021,9（1）:40. doi: 10.21037/atm⁃20⁃4708.
［50］	Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: a population⁃based cohort study［J］. J Allergy Clin Immunol, 2020,145（2）:563⁃571.e8. doi: 10.1016/j.jaci.2019.09.015.
［51］	Droitcourt C, Vittrup I, Kerbrat S, et al. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study［J］. J Am Acad Dermatol, 2021,84（2）:290⁃299. doi: 10. 1016/j.jaad.2020.07.111.
［52］	Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections［J］. Dermatitis, 2020,31（2）:157⁃164. doi: 10.1097/DER.0000 000000000526.
［53］	Han JH, Yoon JW, Yook HJ, et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: a nationwide population⁃based cohort study［J］. J Clin Med, 2022,11（12）:3422. doi: 10.3390/jcm11123422.
［54］	Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2019,80（4）:904⁃912. doi: 10.1016/j.jaad.2018.11.028.
［55］	Choi CW, Yang BR, Suh DI, et al. Infection, antibiotic exposure and development of atopic dermatitis: a nationwide case⁃control study［J］. J Dermatol, 2020,47（7）:707⁃713. doi: 10.1111/1346⁃8138.15387.
［56］	Blicharz L, Usarek P, Młynarczyk G, et al. Nasal colonization by Staphylococci and severity of atopic dermatitis［J］. Dermatitis, 2020,31（3）:215⁃222. doi: 10.1097/DER.0000000000000568.
［57］	Mansfield KE, Schmidt S, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark［J］. JAMA Dermatol, 2020,156（10）:1086⁃1097. doi: 10.1001/jamadermatol.2020.1948.
［58］	Zhu Y, Wang H, He J, et al. Atopic dermatitis and skin cancer risk: a systematic review［J］. Dermatol Ther （Heidelb）, 2022,12（5）:1167⁃1179. doi: 10.1007/s13555⁃022⁃00720⁃2.
［59］	Wang L, Bierbrier R, Drucker AM, et al. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（2）:158⁃171. doi: 10.1001/jamadermatol.2019.3786.
［60］	Cho JM, Davis D, Wetter DA, et al. Association between atopic dermatitis and squamous cell carcinoma: a case⁃control study［J］. Int J Dermatol, 2018,57（3）:313⁃316. doi: 10.1111/ijd. 13857.
［61］	Chou WY, Lai PY, Hu JM, et al. Association between atopic dermatitis and colorectal cancer risk: a nationwide cohort study［J］. Medicine （Baltimore）, 2020,99（1）:e18530. doi: 10.1097/MD.0000000000018530.
［62］	Rafiq M, Hayward A, Warren⁃Gash C, et al. Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: a United Kingdom nationwide case⁃control study［J］. J Allergy Clin Immunol, 2020,145（3）:868⁃876. doi: 10.1016/j.jaci.2019.10.033.
［63］	Hui⁃Beckman JW, Goleva E, Berdyshev E, et al. Endotypes of atopic dermatitis and food allergy［J］. J Allergy Clin Immunol, 2023,151（1）:26⁃28. doi: 10.1016/j.jaci.2022.07.021.
［64］	Rittiphairoj T, Charoenngam N, Ponvilawan B, et al. Atopic dermatitis is a risk factor for rheumatoid arthritis: a systematic review and meta⁃analysis［J］. Dermatitis, 2021,32（1S）:S15⁃S23. doi: 10.1097/DER.0000000000000781.
［65］	Pavel AB, Zhou L, Diaz A, et al. The proteomic skin profile of moderate⁃to⁃severe atopic dermatitis patients shows an inflammatory signature［J］. J Am Acad Dermatol, 2020,82（3）:690⁃699. doi: 10.1016/j.jaad.2019.10.039.
［66］	Leung D, Calatroni A, Zaramela LS, et al. The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype［J］. Sci Transl Med, 2019,11（480）:eaav2685. doi: 10.1126/scitranslmed.aav2685.
［67］	Basu MN, Mortz CG, Jensen TK, et al. Biomarkers in asthma in the context of atopic dermatitis in young children［J］. Pediatr Allergy Immunol, 2022,33（7）:e13823. doi: 10.1111/pai.13823.
［68］	Andersen Y, Egeberg A, Skov L, et al. Comorbidities of atopic dermatitis: beyond rhinitis and asthma［J］. Curr Dermatol Rep, 2017,6（1）:35⁃41. doi: 10.1007/s13671⁃017⁃0168⁃7.
［69］	Fölster⁃Holst R. The role of the skin microbiome in atopic dermatitis⁃correlations and consequences［J］. J Dtsch Dermatol Ges, 2022,20（5）:571⁃577. doi: 10.1111/ddg.14709.
［70］	Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition［J］. Mol Psychiatry, 2017,22（4）:527⁃536. doi: 10.1038/mp.2016.120.
［71］	Sirufo MM, De Pietro F, Bassino EM, et al. Osteoporosis in skin diseases［J］. Int J Mol Sci, 2020,21（13）:4749. doi: 10.3390/ijms 21134749.
［72］	Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis［J］. Am J Clin Dermatol, 2019,20（3）:443⁃456. doi: 10.1007/s40257⁃019⁃00445⁃7.
［73］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［74］	Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient⁃reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health⁃related quality of life in moderate⁃to⁃severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2［J］. J Dermatolog Treat, 2020,31（6）:606⁃614. doi: 10.1080/095466 34.2019.1612836.
［75］	Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis［J］. J Allergy Clin Immunol Pract, 2021,9（3）:1212⁃1223.e6. doi: 10.1016/j.jaip.2020.12.059.
［76］	Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use［J］. Ann Allergy Asthma Immunol, 2022,128（5）:589⁃593. doi: 10.1016/j.anai.2022.01.019.
［77］	Nettis E, Patella V, Lombardo C, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate⁃to⁃severe adult atopic dermatitis［J］. Allergy, 2020,75（10）:2653⁃2661. doi: 10.1111/all.14338.
［78］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［79］	Rubbert⁃Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis［J］. N Engl J Med, 2020,383（16）:1511⁃1521. doi: 10.1056/NEJMoa2008250.
［80］	Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phaseⅢ, double⁃blind, randomized controlled trial［J］. Arthritis Rheumatol, 2019,71（11）:1788⁃1800. doi: 10.1002/art.41032.
［81］	van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis （SELECT⁃AXIS 1）: a multicentre, randomised, double⁃blind, placebo⁃controlled, phase 2/3 trial［J］. Lancet, 2019,394（10214）:2108⁃2117. doi: 10.1016/S0140⁃6736（19）32534⁃6.
［82］	van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Ann Rheum Dis, 2022,81（11）:1515⁃1523. doi: 10.1136/ard⁃2022⁃222608.
［83］	Hasni SA, Gupta S, Davis M, et al. Phase 1 double⁃blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus［J］. Nat Commun, 2021,12（1）:3391. doi: 10.1038/s41467⁃021⁃23361⁃z.
［84］	Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis［J］. Gastroenterology, 2020,158（8）:2139⁃2149.e14. doi: 10.1053/j.gastro.2020.02.030.
［85］	Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease［J］. Gastroenterology, 2020,158（8）:2123⁃2138.e8. doi: 10.1053/j.gastro.2020.01.047.
［86］	冯佩英. 生物制剂治疗特应性皮炎和特应性共病的研究进展［J］. 中山大学学报（医学科学版）, 2022,43（1）:1⁃9. doi: 10. 13471/j.cnki.j.sun.yat⁃sen.univ（med.sci）.2022.0101.
［87］	Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders［J］. Clin Dermatol, 2017,35（4）:360⁃366. doi: 10.1016/j.clindermatol.2017.03.008.
［88］	Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease［J］. Ann Intern Med, 2004,141（10）:764⁃770. doi: 10.7326/0003⁃4819⁃141⁃10⁃200411160⁃00007.
［89］	Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease［J］. J Allergy Clin Immunol, 2016,137（1）:19⁃27. doi: 10.1016/j.jaci.2015.10.023.
［90］	Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036.
［91］	Guttman⁃Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate⁃to⁃severe atopic dermatitis: an integrated analysis of phase 3 studies［J］. J Allergy Clin Immunol, 2023,151（1）:172⁃181. doi: 10.1016/j.jaci.2022.09.023.
［92］	Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseⅢ trials［J］. Br J Dermatol, 2020,183（2）:242⁃255. doi: 10.1111/bjd.18898.

[1]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769.
[2]	胡清洁徐康朱虹姚煦. 老年特应性皮炎患者使用度普利尤单抗治疗的药物留存率及安全性回顾性队列分析[J]. 中华皮肤科杂志, 2024, 57(7): 632-636.
[3]	中华医学会皮肤性病学分会中国康复医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 过敏原特异性IgE检测在特应性皮炎中的临床应用专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(6): 493-502.
[4]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[5]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[6]	赵迎高翠娥隋昕宋志强. 基于高加索人单细胞转录组的炎症性树突状表皮细胞的免疫代谢研究[J]. 中华皮肤科杂志, 2024, 57(4): 343-349.
[7]	刘雅妮赵倩刘源张俊艳王惠平. 特应性皮炎控制工具评估病情控制情况的有效性验证[J]. 中华皮肤科杂志, 2024, 0(4): 20230483-e20230483.
[8]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[9]	陈竹董丽萍肖风丽. 基于代谢组学探究特应性疾病的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220366-e20220366.
[10]	叶慧薛如君张锡宝. 生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220795-e20220795.
[11]	李芳林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230562-e20230562.
[12]	马铜川邓婷月肖风丽. 吸烟与特应性皮炎相关性研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220793-e20220793.
[13]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[14]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[15]	何星燕张珂佳冯燕艳. 新型G蛋白偶联受体X2在皮肤科的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20240124-e20240124.

特应性皮炎共病的研究进展

Comorbidities in atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 92

相关文章 15

Metrics

本文评价

推荐阅读 10